The primary mechanism involves cholelithiasis and resultant cholecystitis and appears to be the driving force in most areas of the arena, whereas GBC is strongly related to gallstone disease, female gender bias, and age over 65.
There are also histologic and molecular differences in GBCs related to anomalous pancreaticobiliary duct junction and in the ones related to gallstones, providing further proof that two different pathogenetic pathways are involved.[4]
GBC arising in Japan within the setting of an anomalous pancreaticobiliary duct junction is characterized by means of KRAS mutations and relatively late onset of p53mutations.[5]
By means of comparison, as a minimum in Chilean patients with cholelithiasis and chronic cholecystitis, KRASmutations are uncommon, while p53 mutations rise up early at some stage in multistage pathogenesis.[6][7]
Less than 3% of early gallbladder carcinomas have adenomatous remnants, indicating this mechanism has less importance within the carcinogenic pathway.[8]
It's hard to predict which of those will go through malignant transformation.
In contrast to properly-established carcinogenic pathways in colorectal most cancers, it remains debated within the literature whether or not or not adenomas are actual precursors of invasivegallbladder carcinomas.
↑ 1.01.1Roa I, de Aretxabala X, Araya JC, Roa J (2006). "Preneoplastic lesions in gallbladder cancer". J Surg Oncol. 93 (8): 615–23. doi:10.1002/jso.20527. PMID16724345.
↑Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF (1995). "Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile". Cancer Res. 55 (12): 2511–5. PMID7780959.
↑Hughes NR, Bhathal PS (2013). "Adenocarcinoma of gallbladder: an immunohistochemical profile and comparison with cholangiocarcinoma". J. Clin. Pathol. 66 (3): 212–7. doi:10.1136/jclinpath-2012-201146. PMID23268317.
↑Solaini L, Sharma A, Watt J, Iosifidou S, Chin Aleong JA, Kocher HM (2014). "Predictive factors for incidental gallbladder dysplasia and carcinoma". J. Surg. Res. 189 (1): 17–21. doi:10.1016/j.jss.2014.01.064. PMID24589178.
↑Mano H, Roa I, Araya JC, Ohta T, Yoshida K, Araki K, Kinebuchi H, Ishizu T, Nakadaira H, Endoh K, Yamamoto M, Watanabe H (1996). "Comparison of mutagenic activity of bile between Chilean and Japanese female patients having cholelithiasis". Mutat. Res. 371 (1–2): 73–7. PMID8950352.
↑Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, Matsubara K, Kawasaki Y, Yamamoto S, Kajiyama G (1999). "Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct". Am. J. Gastroenterol. 94 (6): 1638–42. doi:10.1111/j.1572-0241.1999.01155.x. PMID10364037.
↑Hidaka E, Yanagisawa A, Seki M, Takano K, Setoguchi T, Kato Y (2000). "High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater". Cancer Res. 60 (3): 522–4. PMID10676628.